Silmitasertib

西他舍替

Report date: 2026/03/20 20:03:07
NME

Base Information

Drug NameSilmitasertib
Drug Alias NameSilmitasertibumCX-4945
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCasein kinase II inhibitors
TargetsCasein kinase II
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Community Acquired PneumoniaSolid tumours +[18
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[4
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCylene Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active IndicationsCoronavirus Disease 2019 (COVID-19)Community Acquired PneumoniaSolid tumours +[10
Inactive IndicationsCastleman DiseaseInflammatory Breast NeoplasmsBreast Neoplasms +[8

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank